Literature DB >> 31880854

Chemical components, pharmacological actions, and clinical applications of Rhizoma Picrorhizae.

Ning Guo1,2, Cheng Jin2, Lan Shen1, Fei Wu2, Xiao Lin1, Yi Feng2.   

Abstract

Rhizoma Picrorhizae (RP) is a traditional Chinese medicine, which has always been used to treat many diseases like infantile epilepsy and malnutrition. In modern applications, it has been used to treat hepatitis B and various liver injuries with remarkable curative effects. So far, more than 90 chemical components have been reported in RP, mainly including iridoid glycosides, cucurbitacins, phenylethanoid glycosides, and phenolic glycosides. Among these, iridoid glycosides are the most important active ingredients, and about 30 such compounds have been isolated at present. In pharmacology, RP is beneficial to the choleresis, liver protection, anti-inflammation, asthma relief, immune regulation, and protection of heart, brain, kidney, and other organs. There have been many investigations on this medicinal herb in recent years, and it has attracted much attention in the medicine domain. In this paper, through systematically consulting the relevant books and electronic databases, we analyzed, arranged, and summarized the available information on this herb to provide reference for its further research.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Rhizoma Picrorhizae; clinical use; iridoid glycosides; pharmacology; phytochemistry

Mesh:

Substances:

Year:  2019        PMID: 31880854     DOI: 10.1002/ptr.6591

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  3 in total

Review 1.  Revisiting nature: a review of iridoids as a potential antileishmanial class.

Authors:  Guilherme Arraché Gonçalves; Vera Lucia Eifler-Lima; Gilsane Lino von Poser
Journal:  Phytochem Rev       Date:  2021-03-16       Impact factor: 7.741

Review 2.  Plant-Derived Natural Compounds for the Treatment of Amyotrophic Lateral Sclerosis: An Update.

Authors:  Roohi Mohi-Ud-Din; Reyaz Hassan Mir; Abdul Jalil Shah; Saba Sabreen; Taha Umair Wani; Mubashir Hussain Masoodi; Esra Küpeli Akkol; Zulfiqar Ali Bhat; Haroon Khan
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

Review 3.  The current status of old traditional medicine introduced from Persia to China.

Authors:  Jinmin Shi; Yifan Yang; Xinxin Zhou; Lijun Zhao; Xiaohua Li; Abdullah Yusuf; Mohaddeseh S M Z Hosseini; Fatemeh Sefidkon; Xuebo Hu
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.